ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 249 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $367,201 | -14.3% | 17,620 | -1.5% | 0.03% | -12.9% |
| Q2 2023 | $428,346 | +27.3% | 17,885 | 0.0% | 0.03% | +29.2% |
| Q1 2023 | $336,596 | +18.2% | 17,885 | 0.0% | 0.02% | +9.1% |
| Q4 2022 | $284,729 | -2.8% | 17,885 | 0.0% | 0.02% | -8.3% |
| Q3 2022 | $293,000 | +16.3% | 17,885 | 0.0% | 0.02% | +20.0% |
| Q2 2022 | $252,000 | -41.9% | 17,885 | -0.1% | 0.02% | -31.0% |
| Q1 2022 | $434,000 | +3.8% | 17,910 | 0.0% | 0.03% | +7.4% |
| Q4 2021 | $418,000 | +40.7% | 17,910 | 0.0% | 0.03% | +28.6% |
| Q3 2021 | $297,000 | -32.0% | 17,910 | 0.0% | 0.02% | -38.2% |
| Q2 2021 | $437,000 | -5.2% | 17,910 | +0.1% | 0.03% | -22.7% |
| Q1 2021 | $461,000 | -53.2% | 17,885 | -3.0% | 0.04% | -56.9% |
| Q4 2020 | $985,000 | +24.4% | 18,429 | -4.0% | 0.10% | +67.2% |
| Q3 2020 | $792,000 | -8.9% | 19,204 | +7.2% | 0.06% | -53.4% |
| Q2 2020 | $869,000 | -7.8% | 17,920 | -18.7% | 0.13% | +10.1% |
| Q4 2019 | $943,000 | – | 22,042 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |